HeartCore Enterprises, Inc. — Form 8-K Summary
Reporting date: February 23, 2024, with the Form 8-K signed and filed February 29, 2024. The filing reports a material agreement and related warrant issuance involving Jyo Co., Ltd., a Japanese company. HeartCore is headquartered in Tokyo and trades on Nasdaq under HTCR.
Business Context and Transaction
HeartCore entered into an exclusive Service Agreement with Jyo to provide consulting and support services related primarily to Jyo’s potential U.S. public listing, including Nasdaq listing support, IPO or de-SPAC preparation, financial statement conversion guidance, investor-relations support, translations, and related strategic assistance.
HeartCore will not provide legal or accounting services, act as an investment adviser or broker-dealer, negotiate securities sales, participate in investor discussions, conduct due diligence, or advise on investment valuation or financial advisability.
Financial Terms and Key Metrics
- Phase 1 service fee: $750,000, payable in installments of $250,000 on the effective date, $150,000 within 45 days, $200,000 three months after the effective date, and $150,000 six months after the effective date.
- Phase 2 consideration: A warrant entitling HeartCore to acquire shares representing 2% of Jyo’s fully diluted share capital, subject to adjustment, if the contemplated listing or other qualifying transaction occurs.
- Warrant issued: Initially exercisable for 80 shares of Jyo common stock, representing 2% of Jyo’s issued and outstanding common stock at issuance.
- Exercise price: $0.01 per share, subject to adjustment.
- Exercise period: From the applicable trigger date through the tenth anniversary of that date.
- Equity blocker: Exercise is subject to a 9.99% ownership limitation.
The filing does not provide revenue, net income, cash flow, margin, debt, liquidity, or other company-wide financial statement metrics for the reporting period.
Material Changes Versus Prior Period
The filing text does not provide a prior comparable period or historical financial data. The material change disclosed is HeartCore’s entry into the Jyo Service Agreement and receipt of the related warrant.
Outlook, Risks, Contingencies, and Unusual Items
- The warrant’s value and potential dilution benefit depend on Jyo completing a Nasdaq, NYSE, NYSE American, SPAC, or other qualifying transaction.
- The warrant’s share amount will be adjusted on the trigger date to equal 2% of Jyo’s fully diluted capital following the qualifying transaction.
- The agreement has a maximum stated term of three years from February 23, 2024, or two years after the applicable public-company transaction date, whichever is earlier, unless renewed.
- Either party may terminate upon one month’s written notice, subject to contractual payments. Immediate termination applies for anti-social force activities, with compensation as specified in the agreement.
- The filing does not provide a definitive timetable or assurance that Jyo will complete an IPO, de-SPAC transaction, or other U.S. listing.
- Regulation FD disclosure includes a February 29, 2024 press release, which is furnished rather than filed for Exchange Act Section 18 liability purposes.
Important Facts for Investors to Verify
- Whether and when Jyo pays each installment of the $750,000 Phase 1 fee.
- Whether Jyo completes a qualifying public listing or other trigger transaction.
- The final fully diluted share count, security class, and ownership percentage applicable to the warrant after any adjustment.
- Accounting treatment, collectibility, and timing of revenue recognition for the service fees.
- Potential dilution, valuation, and liquidity of the Jyo warrant if exercised.
- The complete terms of Exhibits 10.1 and 10.2, including termination payments and adjustment provisions.